Published on : Apr 13, 2018
Albany, New York, April 13, 2018: Globally, Rheumatoid Arthritis is one of the most common forms of arthritis. It is chronic, progressive and currently the incurable autoimmune disease that chiefly affects the joints. According to a recent analysis, Rheumatoid arthritis treatment market is expected to grow in coming years due to the increasing demand for more effective drugs and better medical facilities. To elaborate further, Market Research Hub (MRH) has publicized a study titled “Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023” to its vast repository, which offers exclusive insights regarding the current vendor landscape, market forecasts, and its expected performance over the coming years. With a prime focus on Asia Pacific market, the research also compares treatment usage patterns, annual therapy costs, and market growth projections for countries namely India, China, Australia, Japan and South Korea.
Forecast Scrutiny & Key Insights
It has been identified that rheumatoid arthritis has a major negative effect on the ability to perform health-related quality of life daily activities, including work and household tasks. Disease progression results in stiffness and pain, particularly in the hands and feet, which obstructs mobility. Without treatment, the disease leads to joint destruction and disability. In recent times, the RA therapeutic market has become very competitive due to the high number of new drug approvals. According to the analyst evaluations, the Asia-Pacific RA therapeutics market is expected to increase in value at a CAGR of 8.2%, from $5.6 billion to over $9.7 billion during forecast 2016-2023.
Further, it has been analyzed that increasing launches of novel biologics and rising penetration of generic drugs are estimated to provide a noteworthy boost to the market. The current Asia-Pacific RA market contains novel products, including sirukumab, an anti-IL-6 human mAb; Peficitinib, Upadacitinib and Filgotinib, which are JAK1 inhibitors; Olokizumab, an anti-IL-6 humanized IgG4 mAb; and RCT-18. Considering the current market landscape, the research finds that a rising RA prevalence population and the approval of newer therapies will lead to significant market growth over the forecast period, despite the launch of biosimilars of blockbuster anti-TNFs.
Moving further in the study, the research identifies key pipeline trends in terms of molecule type, administration route, molecular target, and novelty. TNF- inhibitors, which dominate the treatment market for RA patients are struggling because 30% of RA patients fail to attain a clinical response when treated with TNF- inhibitors. Though, other targeted programs and newly marketed small-molecule DMARDs such as the Janus kinase (JAK) inhibitor Xeljanz (tofacitinib), have the potential to replace ineffective TNF- inhibitors.
For a clear understanding, the research study market opportunities and potential risks by examining trends in RA clinical trial size, duration, and failure rate by stage of development, molecule type, and molecular target. To conclude with, the research throw lights on therapeutic strategies, products, and companies that dominate the current marketed products landscape.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1701731
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org